Soluble and Cell-associated Hemojuvelins as a Therapy and Diagnostic for Iron Metabolism Diseases
- 技术应用
- rs-hemojuvelin may be used to treat iron disorders that are dependent on hepcidin concentration. Researchers have shown in hepatocytes that rs-hemojuvelin could be administered parenterally to treat anemia of inflammation by inhibiting hepcidin production and releasing iron from sequestration. The increased level of iron stimulates erythrocyte production and thus reverses anemia. GPI-hemojuvelin, rs-hemojuvelin, and s-hemojuvelin, may also be used in assays to monitor or diagnose diseases of iron metabolism.
- 详细技术说明
- Researchers at UCLA have shown that cellular hemojuvelin positively regulates hepcidin mRNA expression, independent of the IL-6 pathway by using hemojuvelin-specific siRNAs to vary hemojuvelin mRNA concentration. From these hemojuvelin studies, UCLA researchers have developed a recombinant soluble form of hemojuvelin (rs-hemojuvelin) and found in blood a naturally occurring soluble form of hemojuvelin, s-hemojuvelin. The recombinant rs- hemojuvelin was shown to inhibit hepcidin production in primary human hepatocytes in a dose-dependent manner. These researchers also found that hemojuvelin with a glycosylphosphatidylinositol-linked membrane anchor (GPI-hemojuvelin) induces hepcidin production thereby decreasing iron levels.
- *Abstract
-
None
- *Applications
-
rs-hemojuvelin may be used to treat iron disorders that are dependent on hepcidin concentration. Researchers have shown in hepatocytes that rs-hemojuvelin could be administered parenterally to treat anemia of inflammation by inhibiting hepcidin production and releasing iron from sequestration. The increased level of iron stimulates erythrocyte production and thus reverses anemia. GPI-hemojuvelin, rs-hemojuvelin, and s-hemojuvelin, may also be used in assays to monitor or diagnose diseases of iron metabolism.
- *IP Issue Date
- May 19, 2009
- *Principal Investigation
-
Name: Tomas Ganz
Department:
Name: Yigal Paul Goldberg
Department:
Name: Lan Lin
Department:
- 附加资料
- Patent Number: US7534764B2
Application Number: US2006427095A
Inventor: Ganz, Tomas | Lin, Lan | Goldberg, Yigal P.
Priority Date: 29 Jun 2005
Priority Number: US7534764B2
Application Date: 28 Jun 2006
Publication Date: 19 May 2009
IPC Current: A61K003800
US Class: 5140011 | 514012 | 5140135
Assignee Applicant: The Regents of the University of California
Title: Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
Usefulness: Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
Summary: (I) is useful for treating, preventing, modulating or attenuating a disease of iron metabolism in a subject, where the disease of iron metabolism is anemia of chronic disease, juvenile hemochromatosis, adult onset hemochromatosis, iron overload, and iron deficiency anemia (claimed). (I) is useful for treating hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis, hepcidin deficiency, transfusional iron overload, thalassemia, thalassemia intermedia, alpha thalassemia, sideroblastic anemia, porphyria, porphyria cutaneatarda, African iron overload, hyperferritinemia, ceruloplasmin deficiency, atransferrinemia, congenital dyserythropoietic anemia, anemia of chronic disease, anemia, hypochromic microcytic anemia, iron-deficiency anemia, conditions with hepcidin excess, Friedreich ataxia, gracile syndrome, Hallervorden-Spatz disease, Wilson's disease, pulmonary hemosiderosis, hepatocellular carcinoma, cancer, hepatitis, cirrhosis of liver, pica, chronic renal failure, insulin resistance, diabetes, atherosclerosis, neurodegenerative disorders, multiple sclerosis, Parkinson's disease, Huntington's disease and Alzheimer's disease.
Novelty: Treating, preventing, modulating or attenuating a disease of iron metabolism, comprises administering a soluble hemojuvelin protein
- 主要类别
- 诊断/治疗
- 细分类别
- 癌症/肿瘤
- 申请号码
- 7534764
- 其他
-
Background
Various diseases of iron metabolism are caused by abnormal hepcidin production, either too much or too little. In the case of anemia of inflammation, the production of hepcidin is stimulated by various cytokines including IL-6. Increased hepcidin levels cause the loss of ferroportin from the surfaces of macrophages engaged in the recycling of iron from senescent red cells. As a result, iron is trapped in macrophages and blood iron concentration decreases, restricting the flow of iron to the bone marrow, and thus slowing the production of hemoglobin and consequently decreasing the production of erythrocytes. In another iron metabolism disease, juvenile hemochromatosis (JH), the decreased expression of hepcidin, is the result of the mutations in the HJV gene. The decreased expression of hepcidin results in severe iron overload.
Tech ID/UC Case
20496/2005-604-0
Related Cases
2005-604-0
- 国家/地区
- 美国
